gamma-L-glutamyl-L-cystéinylglycine

Reported Uses

• NOTE: see Herb & Supplement Effectiveness Rating Definitions table
• aging [Insufficient Evidence]
• alcohol withdrawal sx [Insufficient Evidence]
• Alzheimer dz [Insufficient Evidence]
• angioplasty [Insufficient Evidence]
• athletic performance [Insufficient Evidence]
• cardiovascular dz prevention [Insufficient Evidence]
• cataracts [Insufficient Evidence]
• chronic fatigue syndrome [Insufficient Evidence]
• cirrhosis [Insufficient Evidence]
• cognitive function [Insufficient Evidence]
• cystic fibrosis [Insufficient Evidence]
• glaucoma [Insufficient Evidence]
• idiopathic interstitial pneumonia [Insufficient Evidence]
• nephropathy, contrast-induced [Insufficient Evidence]
• neurotoxicity, cisplatin-induced [Possibly Effective]
• nonalcoholic fatty liver dz [Insufficient Evidence]
• osteoarthritis [Insufficient Evidence]
• Parkinson dz [Insufficient Evidence]

Reported Doses

Safety/efficacy may not be established; reported doses may be derived from limited or potentially inadequate studies w/ variable regimens, multi-ingredient products, or where concentration of active ingredients may vary widely

Effectiveness Ratings

[see Herb & Supplement Effectiveness Rating Definitions table]

angioplasty

[Insufficient Evidence]

Dose: 2.5 g/25 mL IV x1 before procedure, then 2.5 g/25 mL IV x1 given at 24h, 48h, 72h after procedure; Info: product containing glutathione sodium

athletic performance

[Insufficient Evidence]

Dose: 200 mg PO qd

neurotoxicity, cisplatin-induced

[Possibly Effective]

Dose: 1.5-3 g/m^2/dose IV x1 before chemo; Alt: 1.5 g/m^2/dose IV x1 before chemo plus 600 mg IM qd on days 2-5

nonalcoholic fatty liver dz

[Insufficient Evidence]

Dose: 300 mg PO qd